LBA48 Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIb-IV melanoma from SWOG S1801
Year: 2023
Type: conference-abstract
Source: Annals of Oncology
Institutions: The University of Texas MD Anderson Cancer Center, Fred Hutch Cancer Center, Spectrum Health, Corewell Health Blodgett Hospital, University of Utah, Huntsman Cancer Institute, University of Michigan, U-M Rogel Cancer Center, Kaiser Permanente Vallejo Medical Center, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Northwell Health, University of Alabama at Birmingham, University Hospitals of Cleveland, Case Western Reserve University, Emory University, Dana-Farber Cancer Institute, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, National Cancer Institute, National Institutes of Health, Moffitt Cancer Center, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4387809680